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egurgitation in the Artificial Valve Endocarditis
eduction Trial (AVERT) Echocardiography Study
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OBJECTIVES The purpose of this study was to determine the prevalence and severity of paravalvular
regurgitation (PVR) in the Artificial Valve Endocarditis Reduction Trial (AVERT) cohort.
BACKGROUND The initial AVERT cohort consisted of 807 patients randomized to receive either a
Silzone-coated prosthetic valve or a conventional prosthetic valve; early clinical reports
showed higher rates of valve explant caused by PVR for Silzone-coated prosthetic valve.
METHODS Of the 678 eligible patients, 575 (85%) underwent postoperative transthoracic echocardio-
grams. The presence and severity of PVR were identified by color flow Doppler. Reviewers
were blinded to the type of prosthetic valve and the demographic and clinical variables.
RESULTS Among those who underwent echocardiography (Silzone-coated prosthetic valve, n  285
and conventional prosthetic valve, n 290), 59% had prosthetic aortic valves, 32% prosthetic
mitral valves, and 9% had both; demographic and clinical findings (i.e., prosthetic valve
endocarditis, thromboembolism, bleeding, and all-cause death) were similar for the two
groups. Echocardiographically determined PVR was present in 50 valves: Silzone-coated
prosthetic valve, 29 of 285 (10%) and conventional prosthetic valve, 21 of 290 (7%, p  NS);
the severity of PVR was similar in both groups. Kaplan-Meier analysis showed no significant
differences in PVR at 24 months from valve implantation between the two groups (24-month
event-free rate: 93% Silzone-coated prosthetic valve vs. 94% conventional prosthetic valve, p
 NS).
CONCLUSIONS Excluding those patients who had initial prosthetic valve explant, the two-year echocardio-
graphic follow-up of the AVERT cohort shows no statistically significant differences in the
prevalence or severity of PVR in the Silzone-coated prosthetic valve compared with the
conventional prosthetic valve. Further monitoring is warranted to determine whether these
clinical outcomes remain similar on long-term follow-up. (J Am Coll Cardiol 2004;44:
1467–72) © 2004 by the American College of Cardiology Foundationv
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rhe Artificial Valve Endocarditis Reduction Trial (AVERT)
as designed to evaluate the efficacy of the Silzone-coated
rosthetic valve silver-coated sewing ring to reduce pros-
hetic valve endocarditis (PVE), based on studies docu-
enting the safety and efficacy of silver for antimicrobial
rotection (1–3). The purpose of the AVERT study was to
ssess long-term outcomes and evaluate for adverse events
i.e., thromboembolic, bleeding, PVE and/or prosthetic
alve dysfunction). The initial study cohort consisted of 807
atients randomized to receive either a Silzone-coated
rosthetic valve or a conventional prosthetic valve. Although
o differences in thromboembolic events between the two
From the *AVERT Echocardiography Core Laboratory and the Cardiovascular
maging and Clinical Research Core Laboratory, Cardiovascular Division,
ashington University School of Medicine, St. Louis, Missouri; †AVERT Coordi-
ating Center, University of Pittsburgh, Pittsburgh, Pennsylvania; ‡Department of
amily and Preventive Medicine, School of Medicine, University of Utah, Salt Lake
ity, Utah; §St. Paul’s Hospital, Vancouver BC, Canada; Inselspital Bern, Bern,
witzerland; and ¶Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
innesota. The AVERT study was funded by St. Jude Medical, St. Paul, Minnesota.
Manuscript received June 6, 2003; revised manuscript received November 17, 2003,sccepted December 9, 2003.alves were found by the AVERT Data and Safety Moni-
oring Board, reports of a higher incidence of early pros-
hetic valve explant caused by paravalvular regurgitation
PVR) in the Silzone-coated prosthetic valve study arm led
o a discontinuation of recruitment and a worldwide volun-
ary recall of the prosthesis (4,5).
The prevalence and/or clinical significance of PVR after
rosthetic valve replacement has not been well character-
zed. Recent studies seem to suggest that PVR is rather
ommon. When assessed by intraoperative transesophageal
chocardiography, PVR has been reported to be 18% for
ortic valve replacement (AVR) and 23% for mitral valve
eplacement (MVR) (6 – 8). Furthermore, two-year
ollow-up of patients with PVR suggests a benign clinical
ourse, with re-operation required in 1%, usually because
f increased severity of regurgitation.
An estimated 36,000 patients worldwide have received
ilzone-coated prosthetic valve mechanical valves. A recent
eport on the AVERT cohort has shown that the overall
urvival in both groups is similar (5). However, the preva-
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Prevalence of PVR in the AVERT Study October 6, 2004:1467–72ence and severity of PVR in those whose prosthetic valves
ere not explanted early are not known. Long-term
ollow-up of the AVERT study cohort is important to
dentify the prevalence of adverse events, including PVR.
urthermore, long-term follow-up of the AVERT cohort
llows one to further define the rate of progression of PVR.
his report includes demographic, clinical, and transtho-
acic echocardiography (TTE) findings of the available
VERT cohort since the beginning of the study until June
0, 2002. The primary end point of the present study was to
etermine the prevalence and severity of PVR in the
ilzone-coated prosthetic valve and conventional prosthetic
alves. Secondary end points include other TTE-derived
ariables (i.e., ventricular size and function, prosthetic valve
unction) and clinical events (i.e., thromboembolism, bleed-
ng, PVE, and all-cause death).
ETHODS
tudy protocol. The study design, sample-size determina-
ion, and early clinical findings have been presented previ-
usly (4,5). Briefly, the AVERT trial was developed to
etermine whether Silzone-coated prosthetic valve coating
f prosthetic valve sewing rings reduced the risk of PVE.
he trial began recruitment of patients in July 1998, with
he original goal of randomizing 4,400 patients at 12 North
merican and 7 European centers, based on a power
nalysis to detect a 50% reduction in risk of PVE. Recruit-
ent ended in January 2000 because of higher rates of early
rosthetic valve explant resulting from PVR in patients
eceiving a Silzone-coated prosthetic valve. The echocardio-
raphic study was initiated in June 1, 2000, to determine the
revalence and severity of PVR in the remaining AVERT
ohort.
atient population. The AVERT study population com-
rised 807 patients who underwent AVR, MVR, or double
AVR and MVR) valve replacement in North America (n
46) and Europe (n  361); of these, 129 patients were not
ncluded in the present study because they had either died (n
57), had their valves explanted (n  19), withdrew
onsent (n  10), or had not signed informed consent for
Abbreviations and Acronyms
AVERT  Artificial Valve Endocarditis Reduction Trial
AVR  aortic valve replacement
LAA  left atrial area
LV  left ventricular
LVOT  left ventricular outflow tract
MVR  mitral valve replacement
PASP  pulmonary artery systolic pressure
PVE  prosthetic valve endocarditis
PVR  paravalvular regurgitation
RJA  regurgitant jet area
TTE  transthoracic echocardiography
TVI  time-velocity integralhe echocardiography substudy (n  43). Thus, the cohort bvailable for echocardiographic follow-up was 678 patients;
his report describes 575 (85%) of these patients who had at
east one postoperative TTE study performed by June 30,
002. The mean age of the patients was 61 years (range 21
o 85 years), and 214 (43%) were women.
tudy end points. The primary end point of the study was
o determine the incidence and severity of echocardio-
raphically determined PVR. The following classification
as used to assess for PVR: 1) definitive PVR: a regurgitant
et was clearly identified by color flow Doppler as originat-
ng between the prosthetic valve sewing ring and the native
alve annulus; a high-velocity mitral or aortic valve regur-
itant jet was identified by continuous-wave spectral Dopp-
er; and 2) possible PVR: for MVR, a systolic regurgitant jet
as identified within the left atrium, or for AVR a diastolic
et was identified in the left ventricular outflow tract
LVOT) that appeared but could not be clearly identified as
riginating between the prosthetic valve sewing ring and the
ative valve annulus.
The semiquantitative assessment of PVR severity (when
resent), included measurements based on the color flow
oppler, as follows: 1) for MVR, the regurgitant jet area
RJA) was evaluated in multiple views, and the largest RJA
as measured. The RJA was expressed as a percentage of
he left atrial area (LAA) obtained in the same plane as the
aximum regurgitant area (9,10). Mild mitral PVR was
efined as maximum RJA/LAA 20%; moderate mitral
VR between 20% and 40%; and severe mitral PVR as
40%; and 2) for AVR, the prosthetic aortic valve regur-
itation required a measurement of the proximal jet width
valuated in multiple views, and the widest proximal jet
idth was measured. The proximal jet width was expressed
s a ratio to the LVOT diameter obtained from the
arasternal long-axis view. Mild aortic PVR was defined as
ratio of 24%; moderate aortic PVR between 25% and
4%; and severe aortic PVR as 65% (11). Disagreements
etween the two observers in terms of the primary end point
ere settled by consensus.
TE protocol. Complete transthoracic echocardiograms
M-mode, two-dimensional, pulse-wave, continuous-wave,
nd color flow Doppler) were performed in the four stan-
ard views (i.e., parasternal long- and short-axis, and apical
our- and two-chamber views) using commercially available
ltrasound systems. All studies were performed by experi-
nced cardiac sonographers at their respective clinical sites,
ollowing a rigorous echocardiographic protocol designed to
nsure uniformity of studies, which included optimal visu-
lization of the left and right ventricular endocardial bor-
ers, the cardiac chambers, and the native and prosthetic
alves (12,13). Echocardiographic images were stored on
/2 inch videotape (VHS), and the studies were sent to
he AVERT Echocardiography Core Laboratory at Wash-
ngton University for independent review and completion of
easurements by experienced echocardiographers who were
linded to the type of prosthetic valve and the demographic
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October 6, 2004:1467–72 Prevalence of PVR in the AVERT Studynd clinical data. The AVERT Coordinating Center at the
niversity of Pittsburgh performed all statistical analyses.
WO-DIMENSIONAL ECHOCARDIOGRAPHY. Transthoracic
chocardiography was used to obtain measurements of
hamber structure and function and to assess native and
rosthetic valve function. Specifically, the prosthetic valves
ere evaluated for abnormal motion suggestive of dehis-
ence and for abnormal echogenic patterns suggestive of
ndocarditis or thrombosis (13). Measurements of left
entricular (LV) ejection fraction were derived from the
pical four-chamber view at end-diastole and -systole to
btain the LV cavity areas and volumes, by the method of
ummation of disks (14). The LAA was measured at
nd-systole in patients with MVR from the apical four-
hamber view. The LVOT diameter was measured just
elow the aortic valve leaflets at early systole from the
arasternal long-axis view. All echocardiographic measure-
ents were made in three cardiac cycles, and these were
veraged.
ULSE-WAVE, CONTINUOUS-WAVE, AND COLOR FLOW DOP-
LER. The Doppler studies were performed following pre-
iously described techniques for the assessment of native
nd prosthetic mitral and aortic valves (15–18). In patients
ith MVR, the peak diastolic early inflow velocity (E-wave)
nd the diastolic time-velocity integral (TVI) (to determine
ean transvalvular gradient) were obtained by either pulse-
ave or continuous-wave Doppler from the apical four-
hamber view. The ratio of mitral valve TVI to LVOT-TVI
as derived as an index of prosthetic mitral valve regurgi-
ation, with normal values defined as 2.2 (19).
The peak LVOT systolic velocity and TVI were obtained
rom the apical five-chamber view. In patients with AVR,
he peak systolic aortic valve velocity was obtained by
ontinuous-wave Doppler. In patients with tricuspid regur-
itation, the pulmonary artery systolic pressure (PASP, in
m Hg) was calculated from the continuous-wave Doppler
chocardiography velocity as follows: PASP  4(V)2  10,
here V is the peak tricuspid regurgitant jet velocity (in
/s), and 10 mm Hg is the estimated right atrial pressure
20).
Color flow Doppler was performed in all imaging planes
o assess for the presence of native and prosthetic valve
egurgitation. The normal bileaflet prosthetic valve has a
haracteristic central regurgitant jet along the closure line of
he disks that is less than that occurring from the leaflet
inge points. These regurgitant jets can be detected by use
f color flow Doppler according to their characteristic
attern that arise peripherally and converge (inverted
-shape), and/or the origin from the center of the valve and
iverge (V-pattern) (21). Deviations from this pattern,
ncluding large, asymmetric, or eccentric jets that originated
utside of the sewing ring were considered indicative of
VR. The qualitative assessment, as described previously,
efined the presence or absence of PVR, and the semiquan-
itative assessment defined the severity of PVR. itatistical analysis. All measurements are expressed as
ean SD. Comparison between groups was performed by
hi-square analysis for categorical variables and unpaired t
ests for continuous variables. Estimation of rates of PVR
nd postoperative events was made using Kaplan-Meier
nalysis. All statistical calculations were performed using the
AS statistical software (Version 8, SAS Institute, Cary,
orth Carolina).
ESULTS
atient characteristics. Of the 678 available patients, 575
85%) had at least one echocardiographic study after sur-
ery; clinical follow-up was available for all 678 patients.
nitial valve implants included AVR in 59%, MVR in 32%,
nd both AVR and MVR in 9%. The majority of studies
90%) were performed between 12 and 30 months after
rosthetic valve surgery; only a small number of studies were
erformed between 1 and 12 months (4%) or after 30
onths (6%) postoperatively. With the exception of in-
able 1. Clinical Characteristics of AVERT Patients by
chocardiographic Study*
Echocardiographic
Study
(n  575)
No
Echocardiographic
Study (n  166*)
ge (yrs) 61  10 60  13
ender (% male) 58 66
YHA functional class,
I/II/III/IV (%)
10/41/42/7 7/42/41/10
ystolic blood pressure
(mm Hg)
129  20 130  23
iastolic blood pressure
(mm Hg)
72  12 72  13
reoperative LVEF (%) 58  14 56  16
ast medical/surgical
history (%)
Neurologic events
(stroke/RIND/TIA)
5 6
Diabetes mellitus 13 15
Coronary artery disease 31 36
Myocardial infarction 7 13†
Congestive heart failure 21 26
Carotid artery disease 3 6
Coronary artery bypass
surgery
4 7
Heart valve surgery 11 7
Endocarditis
(inactive or recent)
8 8
linical events after valve
implant (%)
Thromboembolism
(all reported)
9 11
Bleeding 8 12
Prosthetic valve
endocarditis
2.6 1.8
All-cause death 2 7†
ll numbers shown are mean  SD, unless noted otherwise. *Excludes patients who
ied or had their prosthetic valves explanted before the start of the echocardiographic
tudy. †p  0.01.
AVERT  Artificial Valve Endocarditis Reduction Trial; LVEF  left ventric-
lar ejection fraction; NYHA  New York Heart Association; RIND  reversible
schemic neurologic deficit; TIA  transient ischemic attack.
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Prevalence of PVR in the AVERT Study October 6, 2004:1467–72reased rates of myocardial infarction and all-cause death,
he baseline characteristics of the group who underwent
TE studies were similar to those who did not (Table 1).
f the 575 patients who underwent TTE, 285 were in the
ilzone-coated prosthetic valve valve group and 290 were in
he conventional prosthetic valve group. The two groups
ere similar in terms of demographic and clinical charac-
eristics (Table 2).
TE. The results of the TTE studies for patients in the
ilzone-coated prosthetic valve and the conventional pros-
hetic valve groups are shown in Table 3. Patient follow-up
imes, LV volumes and ejection fraction were similar be-
ween groups. Definitive PVR was slightly higher in the
ilzone-coated prosthetic valve group compared with the
onventional prosthetic valve group, but this difference did
ot achieve statistical significance. Paravalvular regurgita-
ion was higher in Silzone-coated prosthetic valves in both
itral and aortic positions compared with the respective
onventional prosthetic valves, but these differences likewise
id not achieve statistical significance. Studies with possible
VR were similar between the groups. The severity of PVR
as mild-moderate in nearly all cases. The prevalence of
VR was higher in patients who had MVR (regardless of
alve type) compared with those with AVR (23 of 230 vs. 27
f 397, respectively, p  0.15). There was no echocardio-
raphic evidence of PVE or thrombosis in either group.
The echocardiographic parameters of the AVERT pa-
ients by type of valve are shown in Table 4. There were no
tatistically significant differences between patients who
eceived a Silzone-coated prosthetic valve or a conventional
able 2. Clinical Characteristics of AVERT Patients With
chocardiographic Study by Type of Valve
Silzone-Coated
Valve
Prosthesis
(n  285)
Conventional
Valve
Prosthesis
(n  290)
ge (yrs) 62  10 61  10
ender (% male) 60 56
YHA functional class, I/II/III/IV (%) 11/43/39/7 9/39/46/6
ystolic blood pressure (mm Hg) 129  21 129  19
iastolic blood pressure (mm Hg) 72  12 72  13
ast medical/surgical history (%)
Neurologic events 9 7
Diabetes mellitus 15 11
Coronary artery disease 30 32
Myocardial infarction 5 9
Congestive heart failure 21 21
Carotid artery disease 3 3
Coronary artery bypass surgery 5 4
Heart valve surgery 9 12
Endocarditis (inactive or recent) 7 9
linical events after valve implant (%)
Thromboembolism 9 9
Bleeding 8 9
Prosthetic valve endocarditis 1 4
All-cause death 2 2
ll numbers shown are mean  SD, unless noted otherwise.
There were no statistical differences between the two groups. Abbreviations as inrable 1.rosthetic valve in any of the TTE-derived parameters,
ncluding LV volumes, ejection fraction, peak velocities, and
ime velocity integrals across the prosthetic valves.
The PVR-free rates for both types of prosthetic valves
Kaplan-Meier analysis) showed no significant differences
etween the two valves (Fig. 1). In fact, after 24 months of
ollow-up, the two curves virtually overlap each other, with
imilar PVR-free rates for the Silzone-coated prosthetic
alve and conventional prosthetic valves (91% [95% confi-
ence interval: 88% to 95%] vs. 94% [95% confidence
nterval: 91% to 97%], respectively, p  0.6).
ISCUSSION
chocardiographic follow-up in this AVERT substudy
emonstrates that among patients with study valves in place
t a mean follow-up of 23 months after prosthetic valve
mplant, there were no statistically significant differences in
he prevalence or severity of PVR between the Silzone-
oated prosthetic valve and conventional mechanical valves
n either the mitral or aortic positions. The baseline clinical
haracteristics and postoperative events in this echocardio-
raphic substudy were similar in both groups. Transthoracic
wo-dimensional and color flow Doppler echocardiography
isclosed PVR (combined definite and possible) in 10.9%
or Silzone-coated prosthetic valves versus 8.3% for conven-
ional prosthetic valves. The severity of PVR for both MVR
nd AVR was similar in both prosthetic valve groups. In the
riginal AVERT study cohort of 807 patients, major PVR
able 3. Echocardiographic Parameters of AVERT Patients, by
ype of Valve
Silzone-Coated
Valve
Prosthesis
(n  285)
Conventional
Valve
Prosthesis
(n  290)
chocardiographic follow-up
(months)
23  7 22  8
VEDV (ml) 112 44 108  42
VESV (ml) 48 38 44  35
VEF (%) 61  12 62  12
ll prosthetic valve regurgitation,
n (%)
Definitive 29 (10.2%) 21 (7.2%)
Possible 8 (2.8%) 11 (3.8%)
everity of PVR
Mild 13 (4.6%) 13 (4.5%)
Moderate 13 (4.6%) 9 (3.1%)
Severe 2 (0.7%) 0 (0.0%)
VR, mitral valve n  111 n  119
Definitive 13 (11.7%) 10 (8.4%)
Possible 4 (3.6%) 8 (6.7%)
VR, aortic valve n  201 n  196
Definitive 16 (8.0%) 11 (5.6%)
Possible 4 (2.0%) 3 (1.5%)
ll numbers shown are mean SD, unless noted otherwise. There were no statistical
ifferences between the two groups.
AVERT  Artificial Valve Endocarditis Reduction Trial; LVEDV  left
entricular end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV
left ventricular end-systolic volume; PVR  paravalvular regurgitation.esulting in early prosthetic valve explants was significantly
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alve prosthesis compared with those receiving a conven-
ional prosthetic valve at two-year follow-up (4.4% vs. 1%)
5). The present study excluded those patients who died
efore receiving an echocardiogram, those whose valves had
een explanted early, and those who withdrew study consent
r who had not consented to the echocardiographic sub-
tudy. In addition to PVL, echocardiographic parameters
uch as LV volumes and ejection fraction, and pulse-wave
nd continuous-wave spectral Doppler-derived measure-
ents of prosthetic valve function were similar between the
wo groups, regardless of implant site. These findings
uggest that at an intermediate postoperative follow-up
eriod of approximately two years, ventricular function and
rosthetic valve function are similar in the Silzone-coated
rosthetic valves compared with the conventional prosthetic
alves. Furthermore, clinical events such as thromboembo-
ism, bleeding, PVE, and all-cause mortality were similar in
oth groups.
Transvalvular regurgitation in the closed mechanical valve
rosthesis is an intrinsic feature of normal valve function.
his has been described as “physiologic” regurgitation and is
etected in most bileaflet mechanical valves by use of color
ow Doppler echocardiography (21). Physiologic regurgi-
ant jets are small and confined to the closure margins or at
he hinges of the prosthesis regardless of valve size and are
able 4. Echocardiographic Parameters of AVERT Patients, by
ype of Valve
Silzone-Coated
Valve
Prosthesis
Conventional
Valve
Prosthesis
itral valve prosthesis (n  230) n  111 n  119
rosthetic valve size (mm) 29 2 29  2
VEDV (ml) 114 52 107  38
VESV (ml) 51 46 46  31
VEF (%) 59  13 60  13
eak E-wave velocity (m/s) 1.6 0.4 1.6  0.3
V TVI (cm) 36  9 36  9
V mean gradient (mm Hg) 4.0  1.4 4.0  1.7
atio of: MV TVI/LVOT TVI 1.80  0.47 1.80  0.46
R jet velocity (m/s) 2.6  0.4 2.7  0.4
ASP (mm Hg) 39  9 39  9
ortic valve prosthesis (n  397) n  201 n  196
rosthetic valve size (mm) 23 2 23  2
VEDV (ml) 111 38 109  44
VESV (ml) 46 30 43  36
VEF (%) 62  11 63  11
VOT TVI (cm) 21  5 21  5
VOT peak velocity (m/s) 1.0  0.2 1.0  0.2
oV peak velocity (m/s) 2.3  0.5 2.4  0.5
atio of: LVOT velocity/
AoV velocity
0.43  0.09 0.44  0.11
ll numbers shown are mean SD, unless noted otherwise. There were no statistical
ifferences between the two groups.
AoV  aortic valve; LVEDV  left ventricular end-diastolic volume; LVEF 
eft ventricular ejection fraction; LVESV  left ventricular end-systolic volume;
VOT  left ventricular outflow tract; MV  mitral valve; PASP  pulmonary
rtery systolic pressure; TR  tricuspid regurgitation; TVI  time-velocity integral;
ther abbreviations as in Table 3.emodynamically insignificant. In the normal bileaflet pros- ahesis in the mitral position, physiologic regurgitant orifice
reas range from 0.2 to 1.1 mm2 (21). When assessed by
ntraoperative TEE, PVR is common after prosthetic valve
eplacement, and has been reported as high as 18% for AVR
nd 23% for MVR (6–8). Follow-up studies suggest a
enign long-term prognosis in these patients, with progres-
ion of regurgitation requiring re-operation in 1% of
atients at follow-up 1 to 2 years (6–8,22). The relatively
enign clinical course of the patients in these previous
tudies suggests that incidental findings of PVR in the
bsence of symptoms may be managed conservatively. A
trategy that includes frequent clinical follow-up appears
ustified, with surgical intervention warranted only for those
ho develop clinical symptoms. Previous studies suggest
hat clinical progression is more common in patients with a
istory of previous endocarditis and/or those with severe
alve annulus calcification (23).
Mechanisms responsible for the development of early
VR in the Silzone-coated prosthetic valve have not been
ell defined. It has been suggested that silzone-coating
nhibits normal fibroblast growth into the prosthetic valve
ewing cuff; this is supported by the findings of poor tissue
ngrowth and loosening of sutures in explanted valves in the
VERT study (5). In contrast, PVR that is associated with
ignificant clinical symptoms and/or a rapidly progressive
ourse is often the result of active endocarditis (8). The
resent AVERT echocardiography study, one of the largest
rosthetic valve follow-up studies to date (1,823 valve-years
f follow-up), showed similar PVR rates for both valve
ypes, and combined PVR rates that are lower than those
reviously reported in large series (combined PVR rate of
.7% in the present study). Furthermore, the majority of
ases were of mild or moderate severity (mild: 4.5%,
oderate: 3.8%, severe: 0.3%). Thus, it is possible that some
atients experienced inadequate fibroblast growth into the
rosthetic valve sewing cuff that resulted in the high
ncidence of early valve explants. After a high prosthetic
alve explant rate for the Silzone-coated prosthetic valve,
his intermediate follow-up suggests a similar prevalence of
igure 1. Kaplan-Meier curves for definite paravalvular regurgitation for
ll valves in the AVERT echocardiography substudy (both mitral and
ortic valve replacement).
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Prevalence of PVR in the AVERT Study October 6, 2004:1467–72VR for both prosthetic valves. Whether the severity of
VR in these prosthetic valves increases over time leading to
alve explant is unknown and is the subject of continued
linical and echocardiographic monitoring in the AVERT
ohort.
tudy limitations. Assessment of mechanical prosthetic
itral valve regurgitation by TTE is limited because of
ttenuation and acoustic shadowing of the prosthesis in the
eft atrium. To minimize this potential problem, a number
f well-validated Doppler-derived indices that have been
hown to correlate with significant prosthetic mitral valve
egurgitation were performed, and no differences were
ound between the two groups (19). Transesophageal echo-
ardiography would have been a more sensitive test for PVR
etection in mitral valve prosthesis, but this test was not
outinely performed owing to its semi-invasive nature.
onclusions. Intermediate two-year follow-up of the
VERT cohort shows that among patients with study
alves in place, there are no significant differences by valve
ype in the prevalence or severity of PVR in either the aortic
r mitral valve positions. Although the incidence of reported
VR leading to early prosthetic valve explant was higher in
ilzone-coated prosthetic valves, the prevalence of echocar-
iographically determined parameters (including PVR) as
ell as other clinical parameters were similar among the two
roups. Further monitoring is warranted to determine
hether these clinical outcomes remain similar on long-
erm follow-up.
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